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Introduction: Although susceptibility genes for anti-citrullinated peptide/protein antibodies (ACPA)-positive
rheumatoid arthritis (RA) have been successfully discovered by genome-wide association studies (GWAS), little is
known about the genetic background of ACPA-negative RA. We intended to elucidate genetic background of
ACPA-negative RA.
Method: We performed a meta-analysis of GWAS comprising 670 ACPA-negative RA and 16,891 controls for 1,948,138
markers, followed by a replication study of the top 35 single nucleotide polymorphisms (SNPs) using 916 cases and 3,764
controls. Inverse-variance method was applied to assess overall effects. To assess overlap of susceptibility loci between
ACPA-positive and -negative RA, odds ratios (ORs) of the 21 susceptibility markers to RA in Japanese were compared
between the two subsets. In addition, SNPs were stratified by the p-values in GWAS meta-analysis for either ACPA-positive
RA or ACPA-negative RA to address the question whether weakly-associated genes were also shared. The correlations
between ACPA-positive RA and the subpopulations of ACPA-negative RA (rheumatoid factor (RF)-positive and
RF-negative subsets) were also addressed.
Results: Rs6904716 in LEMD2 of the human leukocyte antigen (HLA) locus showed a borderline association with
ACPA-negative RA (overall p = 5.7 × 10−8), followed by rs6986423 in CSMD1 (p = 2.4 × 10−6) and rs17727339 in FCRL3
(p = 1.4 × 10−5). ACPA-negative RA showed significant correlations of ORs with ACPA-positive RA for the 21 susceptibility
SNPs and non-HLA SNPs with p-values far from significance. These significant correlations with ACPA-positive RA were
true for ACPA-negative RF-positive and ACPA-negative RF-negative RA. On the contrary, positive correlations were not
observed between the ACPA-negative two subpopulations.
Conclusion: Many of the susceptibility loci were shared between ACPA-positive and -negative RA.* Correspondence: ohmurako@kuhp.kyoto-u.ac.jp
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Rheumatoid arthritis (RA) is the most common auto-
immune arthritis worldwide with prevalence of around 1%.
Genetic factors as well as environmental factors are involved
in the development of RA [1]. HLA, especially HLA-DRB1,
is the strongest susceptibility locus to RA beyond ethnicity.
Anti-citrullinated peptide/protein antibody (ACPA) is a
highly specific autoantibody to RA, which recognizes a
broad range of citrullinated peptides and appears in approxi-
mately 80% of patients with RA [2-4]. Previous studies ad-
dressing the genetic difference between RA subsets with or
without ACPA have shown that ACPA-negative RA has dif-
ferent susceptibility human leukocyte antigen (HLA) alleles
from ACPA-positive RA [5-8]. A recent study in Europeans
also confirmed the different susceptibility HLA alleles in the
context of susceptibility effects of amino acid residues [9].
Recent genome-wide association studies (GWAS) have
identified more than 40 non-HLA susceptibility loci in
Europeans and Asians [10-22] and these studies have also
shown overlapped susceptibility loci among different pop-
ulations [14,22] as well as ethnicity-specific susceptibility
loci [12,13,23]. Previous GWAS analyzed ACPA-positive
RA or RA regardless of ACPA positivity. Evidence on the
genetic background of ACPA-negative RA is quite limited,
and there are only a few GWAS addressing ACPA-
negative RA from the European population [24,25]. The
GWAS failed to identify specific susceptibility loci to
ACPA-negative RA beyond the GWAS significance level.
Several studies from mainly European countries using
candidate gene approach have reported susceptibility
markers to ACPA-negative RA [26-30], but none of them
were specific to ACPA-negative RA with strong P-values,
due to their limited numbers of subjects.
In addition to previous reports of different HLA suscep-
tibility alleles to ACPA-positive and -negative RA, one UK
study reported different associations of RA susceptibility
loci between ACPA-positive and -negative RA [27]. On
the contrary, another study from the US reported that
ACPA-negative RA shares large fractions of susceptibility
loci with ACPA-positive RA except for HLA [31]. Thus,
similarities and differences in genetic components be-
tween ACPA-negative and -positive RA are inconclusive.
Furthermore, previous studies suggest that ACPA-
negative RA has two distinct subsets based on rheuma-
toid factor (RF) positivity in association with HLA
alleles [32,33]. No studies have ever addressed whether
the two ACPA-negative subsets share non-HLA suscep-
tibility alleles with ACPA-positive RA or with each
other. Moreover, there are no GWAS or candidate gene
studies addressing non-HLA locus in ACPA-negative
RA from an Asian population, except for a subanalysis
of GWAS against RA in a Chinese population [34]. A
GWAS of ACPA-negative RA subjects from an Asian
population may identify novel susceptibility loci toACPA-negative RA, which were not found in the previ-
ous European GWAS due to lack of power, or which are
specific to the Asian population. Asian GWAS would
also elucidate overlapping and dissociations of suscepti-
bility loci between ACPA-positive and -negative RA in
the Asian population, including detailed analysis for the
two subsets of ACPA-negative RA.
Here, to elucidate the genetic background of ACPA-
negative RA for the first time in the Asian population,
we performed a meta-analysis of GWAS comprising 670
patients with ACPA-negative RA and 16,891 controls in
a Japanese population, followed by a replication study of
916 cases and 3,764 controls. We also analyzed genetic
correlations between ACPA-positive and -negative RA
or the two subsets of ACPA-negative RA based on RF
positivity.Methods
Ethics statement
This study was designed in accordance with the Helsinki
Declaration. This study was approved by the local ethics
committees, namely, Kyoto University Graduate School
and Faculty of Medicine, Ethics Committee and Ethics
Committees of RIKEN, Tokyo Women’s Medical University
Matsuyama Red Cross Hospital, Keio University School of
Medicine, Dohgo Spa Hospital, Niigata Rheumatic Center,
Higashihiroshima Memorial Hospital, Kurashiki Sweet
Hospital and Pharm C, Matsubara Mayflower Hospital.
Written informed consent was obtained from all study
participants. All data were de-identified and analyzed
anonymously.Study subjects
A total of 670 patients with ACPA-negative RA and
16,891 controls were enrolled in the three GWAS from
RIKEN, Kyoto University, and Tokyo Women’s Medical
University, respectively, and 916 cases and 3,764 con-
trols in the replication study. The subjects in GWAS
were included in the meta-analysis of RA recently
reported from GARNET consortium [14] (RA meta-
analysis hereafter). A summary of the participants is
presented in Table 1. All of the patients fulfilled American
College of Rheumatology (ACR) revised criteria for RA in
1987 [35] or ACR and European League Against Rheuma-
tism (EULAR) classification criteria for RA in 2010 [36].ACPA detection
The MESACUP CCP ELISA kit (Medical and Biological
Laboratories Co., Ltd, Nagoya, Japan) was used to detect
second-generation ACPA in each RA patient, according
to the manufacturer’s instructions. A cutoff value of
4.5 U/ml was used to define ACPA positivity.
Table 1 Summary of study subjects
Cases Controls
GWAS meta-analysis
Number of subjects 670 16,891
Cohort Kyoto, BBJP, IORRA BBJP
Age* 60.4 ± 18.9 60.9 ± 12.5
Female ratio 81.6% 44.9%
Genotyping platform Illumina HumanHap610-Quad BeadChip Illumina HumanHap610-Quad BeadChip
Illumina HumanHap300 BeadChip
Illumina Human CNV370-Duo BeadChip
Affymetrix Genome-wide Human SNP Array 6.0
RF positivity 46.3% -
Replication study
Number of subjects 916 3,764
Cohort Kyoto, BBJP, IORRA Kyoto University
Age* 62.9 ± 13.7 59.3 ± 14.2
Female ratio 77.8% 48.4
Genotyping platform Taqman Assay Illumina HumanHap610-Quad BeadChip
Illumina HumanHap550 BeadChip
RF positivity** 40.0% -
*Mean ± standard deviation. **Rheumatoid factor (RF) positivity rate of samples with RF data available. GWAS, genome-wide association studies; BBJP, Biobank
Japan; IORRA, cohort of Tokyo Women’s Medical University; SNP, single nucleotide polymorphism.
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The serum RF concentrations of samples were quantified
using a latex agglutination turbidimetric immunoassay
or an ELISA assay. When multiple values for RF had
been obtained at different visits, we used the maximum
RF value for each patient. The cutoff values of each de-
tection kit in each hospital were employed.
Genotyping
Microarrays in Illumina Infinium and Affymetrix were used
for the meta-analysis of the three GWAS. Detailed informa-
tion on the arrays was given in the previous report [14]. In
the replication study, Taqman assays were performed for
genotyping case subjects, and genotype data for controls
were extracted from array data of Illumina Infinium
HumanHap610-Quad or HumanHap550 (Table 1). Associ-
ation data for 2,822 patients with ACPA-positive RA and
16,891 controls were obtained from the RA meta-analysis.
We applied the same quality-control criteria as the RA
meta-analysis including call rate, minor allele frequency,
and Hardy-Weinberg disequilibrium: these details were
presented in the previous manuscript [14].
Imputation
Imputed genotype data of ACPA-negative RA patients was
extracted from the RA meta-analysis in a Japanese popula-
tion. Briefly, MACH version 1.0.16 software was used for
imputation of genotype data obtained by the GWAS of RAwith the Hapmap phase II East Asian panel (JPT and CHB)
as reference. As the meta-analysis in the current study in-
cluded three different GWAS, the imputation was per-
formed separately for data from each GWAS using the
same reference panel. A total of 1,948,138 single nucleotide
polymorphisms (SNPs) with minor allele frequency >1%
and imputation score (Rsq) >0.5 were used for the analysis.
Thirteen regions associated with ACPA-negative RA in a
European population
SNPs in the 13 regions that were reported to be associated
with ACPA-negative RA in a European population were
extracted from the GWAS meta-analysis. The 13 SNPs
that had the strongest associations among the 13 regions
were selected as representatives of the regions. We per-
formed a total of 20,000 permutation tests to evaluate em-
pirical P-values to obtain the smallest P-values <0.01 from
4 of the 13 regions.
SNP selection for the replication study
SNPs with P-values <1 × 10−4 in the GWAS meta-analysis
and contained in both the Illumina Infinium HumanHap
610-Quad array and the Human Hap 550 array, and for
which real-time PCR primers and probes were successfully
designed, were selected for the replication study. Rs3889769
was excluded due to difficulty in designing probes for the
replication study. The 21 SNPs that were shown to be sus-
ceptibility markers in the RA meta-analysis and were
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610-Quad array and the Human Hap 550 array were
also selected for the replication study to analyze correl-
ation of effect sizes (odds ratio, OR) between ACPA-
negative and -positive RA. For FCRL3, rs17727339,
which had a strong association with ACPA-negative RA,
was used in the analysis.
Assessment of heterogeneity
Heterogeneity among three GWAS or among the GWAS
and the replication study was evaluated by the Cochran
Q-test and I2.
Correlation analysis
Effect sizes (ORs) of risk alleles in the 21 SNPs were com-
pared between ACPA-positive and -negative RA by calculat-
ing the Spearman correlation coefficient in the GWAS
meta-analysis and the replication study. Correlation of effect
sizes for non-HLA SNPs in GWAS meta-analysis was ana-
lyzed between ACPA-positive and -negative RA, -negative
RF-positive or -negative RF-negative RA by Spearman’s cor-
relation coefficient for SNPs pruned by r2 <0.3 by PLINK
with intervals of P-values. Data for r2 was obtained in the
Hapmap phase II JPT data. HLA was defined from 25 Mbp
to 35 Mbp on chromosome 6 based on NCBI build 36.
Statistical analysis
Dosage of risk alleles were assessed for associations with
susceptibility to ACPA-negative RA by logistic regres-
sion analysis. The inverse-variance method was used to
combine results of the three GWAS in the meta-analysis
assuming a fixed-effect model from study-specific effect
sizes (logarithm of ORs) and to combine results of the
GWAS meta-analysis and the replication study. The QQ
plot was used to assess population structure in the
GWAS meta-analysis. Genomic control methods were
applied to the test statistics in each of the three GWAS
of ACPA-negative RA patients based on the inflation
factor calculated in each study. Because the meta-
analysis of the three GWAS did not show an inflation
factor >1.0, we did not apply genomic control to the re-
sults of the meta-analysis. We also performed GWAS
meta-analysis using age and sex as covariates. Statistical
analyses were performed by R software or PLINK ver-
sion 1.07 [37]. P-values <0.05 and 5 × 10−8 were regarded
as significant for correlation analyses and GWAS,
respectively.
Results
The overall strategies of our study are demonstrated in
Additional file 1. First, a total of 670 patients with ACPA-
negative RA from three independent cohorts (GARNET
Consortium detailed in Methods) and 16,891 controls were
genome-scanned with different SNP typing platforms(Table 1) and the data were imputed separately using the
same Hapmap phase II East Asian panel as reference and
corrected in order to fit meta-analysis as detailed in
Methods. The QQ plot of the GWAS meta-analysis did not
show evidence of population stratification (lambda = 0.98,
Additional file 2). Thus, we did not apply genomic control
to our GWAS results. The result of the GWAS meta-
analysis is shown in Figure 1 and no markers, including the
HLA locus, reached the GWAS significant level. However,
when we focused on our results in the GWAS meta-analysis
of the genes that had been reported to be associated with
ACPA-negative RA in the previous studies, four out of the
13 genes had SNPs with suggestive association (P <0.01)
(Additional file 3). This ratio was significantly higher than
the ratio obtained by chance based on 20,000 permutations
(permutation P= 0.017). We confirmed that the effect sizes
and Manhattan plot in the meta-analysis were almost identi-
cal to those in the meta-analysis using age and sex as covari-
ates (Additional files 4 and 5).
Next, we performed a replication study by selecting 35
SNPs that showed suggestive associations with ACPA-
negative RA in the GWAS meta-analysis (Additional file 6,
P <1.0 × 10−4; for detail see Methods). An independent set
of 916 patients with ACPA-negative RA and 3,764 controls
were used for the replication study using the Taqman Assay.
As a result, 3 out of the 35 SNPs, namely, rs6904716 in
LEM domain containing 2 (LEMD2) on the HLA locus,
rs17727339 in Fc receptor like 3 (FCRL3) on chromosome 1,
and rs6986423 in CUB and Sushi multiple domains 1
(CSMD1) on chromosome 8, showed the same direction of
risk alleles as the GWAS meta-analysis with P-values <0.05
(Table 2). None of these three SNPs showed deviation from
Hardy-Weinberg equilibrium (P ≥0.039). In the combined
study using the inverse-variance method, rs6904716, which
is contained in the HLA locus, had borderline association
(P= 5.7 × 10−8). These three SNPs did not show significant
heterogeneity among the three GWAS and among the
GWAS and the replication study (Table 2). While rs6986423
showed a moderate heterogeneity, the P -value based on Q-
statistics was not significant (P= 0.076).
Although we did not find any variants associated with
ACPA-negative RA with P-values beyond the GWAS
significance level, we hypothesized that ACPA-negative
RA shares a large part of the susceptibility loci with
ACPA-positive RA. To test this hypothesis, we com-
pared the ORs of the associated SNPs in ACPA-positive
RA with those in ACPA-negative RA. First we selected
the 21 non-HLA susceptibility SNPs in the RA meta-
analysis in a Japanese population [14] (for detail see
Methods). As shown in Figure 2A, ORs of the 21 SNPs
for ACPA-negative RA are clearly correlated with those
for ACPA-positive RA (r = 0.65, P = 0.0014, Figure 2A
and detailed in Additional file 7). These 21 SNPs were
also genotyped for the replication study (916 patients
Figure 1 Manhattan plot of meta-analysis of three genome-wide association studies (GWAS) for anti-citrullinated peptide/protein antibody-negative
rheumatoid arthritis. The horizontal line indicates the GWAS significance level (P = 5 × 10−8).
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again the significant association of ORs between the two
RA subsets was obtained (r = 0.45, P = 0.038, Figure 2A
and detailed in Additional file 7). These results strongly
suggest that ACPA-negative RA shares non-HLA suscep-
tibility loci with ACPA-positive RA (Figure 2B).
Next, to address the question as to whether weakly as-
sociated genes are also shared between ACPA-positive
and -negative RA, SNPs were stratified by the P-values
in the GWAS meta-analysis for either ACPA-positive
RA or ACPA-negative RA and correlation coefficients of
ORs for the SNPs in each stratified fraction were plotted.
As shown in Figure 2C, the smaller the P-values, the
bigger the correlation coefficients. These results suggest
that the susceptibility loci of ACPA-positive RA and
ACPA-negative RA are largely overlapped and the effect
size of each SNP is similar between the two RA subsets.
Last, because our recent study showed that ACPA-
negative RA consists of two genetically different subsets in
terms of HLA-DRB1 usage, that is, ACPA-negative RF-
positive RA and ACPA-negative RF-negative RA [32,33], as-
sociations of non-HLA markers were compared between
these two ACPA-negative subsets. As shown in Figure 3A
and B, ORs for SNPs in ACPA-positive RA were correlated
with those in ACPA-negative RF-positive RA and ACPA-
negative RF-negative RA. In particular, ORs for SNPs show-
ing suggestive associations (P <0.001) with ACPA-positive
RA also had strong correlation with ACPA-negative RF-
positive RA (r= 0.47, Figure 3A). On the contrary, when
correlations of ORs were analyzed between ACPA-negative
RF-positive RA and ACPA-negative RF-negative RA, no
positive associations were observed, even for the SNPs sug-
gestive associations (P <0.001) (Figure 3C). These results
suggest that ACPA-positive RA is genetically similar to
ACPA-negative RF-positive RA rather than ACPA-negative
RF-negative RA.Discussion
Because the number of studies addressing susceptibility
loci to ACPA-negative RA including candidate gene ana-
lyses is quite limited, this is the first report of GWAS ad-
dressing ACPA-negative RA in an Asian population and
one of the largest in the world [24,25]. Our study re-
vealed that ACPA-negative RA shares a large proportion
of susceptibility loci with ACPA-positive RA for non-
HLA alleles. Moreover, our results suggest that ACPA-
negative RA consists of two genetically distinct subsets
based on RF positivity even for non-HLA genes. Our
study participants showed 45.5% of positivity of RF, com-
patible to the previous ACPA-negative RA cohorts [9].
We confirmed that inclusion of age and sex as covari-
ates did not alter the results. This means that as the
prevalence of RA is around 1% and the controls are not
young, the influence of contamination of subjects among
controls who develop RA in the future should be very
small.
Our study confirmed an association between ACPA-
negative RA and the HLA locus and revealed suggestive
associations of FCRL3 on chromosome 1 and CSMD1
on chromosome 8. We did not find heterogeneity among
the studies, indicating that these associations were not
obtained by one or two studies with extreme association.
While the female ratio was different between cases and
controls, we did not adjust for sex. This is because most
of the previous GWAS, including our previous meta-
analysis, did not adjust for sex to analyze autosomal
SNPs.
Because rs6904716 in the HLA locus was not very
strongly associated with ACPA-positive RA in the RA
meta-analysis [14], these results suggest that associated
HLA alleles are different between ACPA-positive and
ACPA-negative RA. Low effect sizes of the HLA locus to
ACPA-negative RA may explain the lack of significant
Table 2 Association of the top 3 SNPs with ACPA-negative RA among the 35 replicated SNPs
SNP Chr Position Gene Exon/
intron
Ref Var GWAS Replication study Combined study
Beta SE P I2 (%) Beta SE P P OR (95% CI) I2 (%)
rs6904716 6 33849267 LEMD2 intron A G −0.309 0.074 2.7 × 10−5 0 −0.219 0.061 0.00036 5.7 × 10−8 0.77 (0.70, 0.85) 0
rs6986423 8 4621823 CSMD1 intron G T −0.248 0.057 1.4 × 10−5 55.9 −0.128 0.053 0.017 2.4 × 10−6 0.83 (0.77, 0.90) 61.3
rs17727339 1 155946738 FCRL3 - C T −0.262 0.066 8.0 × 10−5 0 −0.142 0.063 0.025 1.4 × 10−5 0.82 (0.75, 0.90) 0














Figure 2 Correlation of odds ratios (ORs) of rheumatoid arthritis (RA) susceptibility single nucleotide polymorphisms (SNPs) for anti-citrullinated
peptide/protein antibody (ACPA)-positive RA and those for ACPA-negative RA. (A) Correlations of ORs regarding the 21 susceptibility SNPs to RA
for ACPA-positive and -negative RA. The upper panel shows the results in the genome-wide association studies (GWAS) meta-analysis and the
lower panel shows the results in the replication study. (B) ORs of the 21 SNPs in RA-susceptibility loci for ACPA-negative RA in the combined
analysis (blue line) and ACPA-positive RA (red line) are plotted. Mean +/− 95% CI are shown. (C) Correlation coefficient of ORs between
ACPA-positive and -negative RA in terms of SNPs stratified by P-values for ACPA-positive RA. *P-values <1.0 × 10−7. SNPs in the HLA locus were
excluded from this analysis.
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GWAS.
FCRL3 has been reported to be associated with RA,
especially in the Japanese population [38]. Rs7528684 is
considered to be the causative variant of the FCRL3 re-
gion to which NFκB binds and activates B cells to pro-
duce antibody by augmenting BCR-mediating signals
[38]. Rs17727339 is in moderate linkage disequilibrium
(LD) with rs7528684 (D’:0.80 and r2:0.28). Although the
association of rs17727339 in the combined study did not
reach the GWAS significant level, the replication studysupported the association of FCRL3 with ACPA-negative
RA. Thus, it is likely that the FCRL3 region, possibly as
a consequence of association of rs7528684, is associated
with both ACPA-positive and -negative RA.
CSMD1 is a tumor-suppressor gene associated with
psoriasis, Kawasaki disease and schizophrenia [39-41].
CSMD1 expresses mainly in epithelial cells and exhibits
anti-tumor activity through activation of the Smad path-
way [42,43]. CSMD1 also functions as a complement
regulatory gene, especially of the classical pathway [43].
Thus, the role of CSMD1 on complement or other genes
Figure 3 Correlations of odds ratios (ORs) in sets of non-human
leukocyte antigen (HLA) single nucleotide polymorphisms (SNPs) among
anti-citrullinated peptide/protein antibody (ACPA)-positive rheumatoid
arthritis (RA) and the two subsets of ACPA-negative RA. Correlation
coefficient of ORs between ACPA-positive RA and ACPA-negative
RF-positive RA (A), between ACPA-positive RA and ACPA-negative
RF-negative RA (B), and between ACPA-negative RF-positive RA and
ACPA-negative RF-negative RA (C), in terms of SNPs stratified by p-values
of ACPA-positive RA (A, B) or each study (C). *Positive correlation with
P-values <1.0 × 10−7. SNPs in the HLA locus were excluded from
this analysis.
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velopment of ACPA-negative RA. This chromosome 8
region was not associated with ACPA-positive RA in the
RA meta-analysis (P = 0.87), therefore, this region may
be an ACPA-negative RA-specific associated region.
Considering the moderate heterogeneity of rs6986423,
further replication studies would confirm the association
between this region and ACPA-negative RA.
Four regions out of the thirteen genes that had been
shown to be associated with ACPA-negative RA in Euro-
pean populations had P-values <0.01 (Additional file 3)
in the Japanese population. Although these markers did
not reach the stringent significance level, the current re-
sults suggest that ACPA-negative RA shares susceptibil-
ity loci beyond ethnicity.
Although we did not find ACPA-negative RA-
associated genes with a GWAS-significance level due to
the limited power of case subjects, the current results
suggested that the majority of non-HLA susceptibility
loci are shared between ACPA-positive and ACPA-
negative RA. Correlation analysis of the 21 SNPs in the
susceptibility loci to Japanese RA showed significant cor-
relations of ORs between ACPA-positive and ACPA-
negative RA in both the GWAS meta-analysis and the
replication study. These consistent correlations support
similarity of genetic background between the two RA
subsets. Such results are consistent with the previous US
report that compared the ORs of representative SNPs in
29 RA susceptibility loci of European ancestry between
ACPA-positive RA and ACPA-negative RA. We also
showed that the ORs for SNPs weakly associated with
ACPA-positive RA are correlated with ACPA-negative
RA, with the strength of correlation depending on the
strength of the P-values for the association. While the
UK study emphasized the categories of susceptibility loci
(for example, some genes are associated only with
ACPA-positive RA and some genes with both ACPA-
positive and ACPA-negative RA), we assume that the
majority of the susceptibility loci are shared between
ACPA-positive and ACPA-negative RA. Because the re-
sults of susceptibility analysis for genes with a small ef-
fect size vary by the sample size, correlation analysis of
effect size may be more powerful than the orthodox as-
sociation analysis in such cases. In fact, when we calcu-
lated the correlation of ORs for the 35 non-HLA SNPs
from the table in the UK study [27], the correlation coeffi-
cient was 0.63, showing that many of the genes are shared
between ACPA-positive and -negative RA. These strong cor-
relations between ACPA-positive and -negative RA matches
with the current study as well as the US study [31].
On the contrary, HLA-association seems to be differ-
ent between ACPA-positive and -negative RA. We and
others have already shown that the HLA-DRB1 allele
usage in ACPA-negative RA is different from that in
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the previous results, including those of the UK studies
[23,25], in that rs6904716, which had the smallest P-
value for ACPA-negative RA in the current study, did
not show strong association in ACPA-positive RA in the
RA meta-analysis (P = 2.3 × 10−15) compared with other
SNPs in the HLA locus (the smallest P = 1.2 × 10−130),
whereas rs7764819, displaying the strongest association
in the HLA locus with ACPA-positive RA in the RA
meta-analysis, did not even show a suggestive associ-
ation with ACPA-negative RA in the current study (P =
0.56). All these results confirmed the idea that ACPA-
negative RA uses the different HLA allele from ACPA-
positive RA. These results may suggest that T cells in
ACPA-positive RA react against relatively uniform auto-
antigens, citrullinated proteins, whereas T cells in
ACPA-negative RA react with varied autoanitigens.
In the current study, we also confirmed that the two sub-
sets of ACPA-negative RA, ACPA-negative RF-positive RA
and ACPA-negative RF-negative RA, are genetically dis-
tinct. Previously we reported that the HLA allele usage is
different between the two ACPA-negative RA subsets [30].
Here we showed that not only HLA allele usage but also
the association of non-HLA genes is different (Figure 3C).
As Figure 3A and B show, ACPA-negative RF-positive RA
is genetically closer to ACPA-positive RA than ACPA-
negative RF-negative RA. Therefore, only ACPA-negative
RF-negative RA may be a relatively different subset from
conventional RA including ACPA-negative RF-positive RA
(see Additional file 8).
Because ACPA-negative RA represents a minor subset
of RA, it is difficult to perform the association analysis to
detect common variants with small effect sizes. In such
cases, correlation analysis of effect size of each SNP may
be more powerful to determine whether two different sub-
sets share the majority of susceptibility loci or not. We as-
sume that many of the susceptibility loci are shared except
for the HLA allele between ACPA-positive and -negative
RA, but worldwide meta-analysis would be necessary to
confirm this idea.Conclusions
Two non-HLA loci showed suggestive associations with
ACPA-negative RA in the Japanese population. ACPA-
negative RA, especially the RF-positive subset, shares a
common genetic background with ACPA-positive RA.Additional files
Additional file 1: Study design of the current study. A flow of the
current study design is indicated.
Additional file 2: QQ plot of the genome-wide association studies
(GWAS) meta-analysis. The observed and expected P-values are indicated.Additional file 3: Association of 13 regions reported to be associated
with anti-citrullinated peptide/protein antibody (ACPA)-negative
rheumatoid arthritis (RA) in European populations. The results of the best
P-values in the 13 regions reported to be associated with ACPA-negative RA
in European populations are indicated.
Additional file 4: Strong correlations of effect sizes in single
nucleotide polymorphisms (SNPs) between analyses with or without
age and sex as covariates. The effect sizes in SNPs pruned by linkage
disequilibrium (r2 > 0.3) are compared between analysis with or without
age and sex as covariates and plotted.
Additional file 5: Manhattan plot of the genome-wide association
studies (GWAS) meta-analysis using age and sex as covariates. The
results of the meta-analysis are plotted according to the chromosomal
positions and P-values.
Additional file 6: Replication results for all of the regions showing
P-values <0.0001 in the genome-wide association studies (GWAS)
meta-analysis. The combined results are also indicated.
Additional file 7: Results of the 21 single nucleotide polymorphisms
(SNPs) in the regions associated with RA in anti-citrullinated peptide/
protein antibody (ACPA)-positive and -negative RA. The results in
ACPA-positive and -negative rheumatoid arthritis (RA) are indicated for the 21
SNPs in the regions associated with RA in the RA genome-wide association
studies (GWAS) meta-analysis.
Additional file 8: Schematic image of overlapping of susceptibility
alleles among anti-citrullinated peptide/protein antibody (ACPA)-positive
and the two subsets of ACPA-negative RA. Schematic image of overlapping
of susceptibility alleles among ACPA-positive and the two subsets of
ACPA-negative rheumatoid arthritis (RA) is indicated based on the previous
and current results.
Abbreviations
ACPA: anti-citrullinated peptide/protein antibody; ACR: American College of
Rheumatology; ELISA: enzyme-linked immunosorbent assay;
GWAS: genome-wide association study; HLA: human leukocyte antigen;
LD: linkage disequilibrium; OR: odds ratio; RA: rheumatoid arthritis;
RF: rheumatoid factor; SNP: single nucleotide polymorphism.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CT analyzed the overall data. YO performed the permutation tests. CT, YO,
TK, and RY contributed to the GWAS data. CT, KO, YK, KI, SMo, KY, and FM
designed the study. CT, KO, YK, KI,NN, AS, MT, KT, AM, SMi, MI, KF, MN, MF,
MH, HI, TF, KE, TMa, TT, MK, AT, HY, SMo, KY, and TMi contributed to
acquisition of data. CT, MS, KI, and KM performed the replication study. CT
and KO drafted the manuscript. All authors revised the manuscript and read
and approved the final manuscript.
Acknowledgements
The authors acknowledge the essential role of the GARNET consortium in
developing the study. In this study, the following GARNET members are
included: CGM of RIKEN, University of Tokyo, the BioBank Japan Project,
Kyoto University and IORRA. We would like to thank all the doctors and staffs
who participated in sample collection for the RIKEN cohort and the BioBank
Japan Project. We thank K Kobayashi and M Kitazato for their technical
assistance. We thank M Kokubo for DNA extraction, GWAS genotyping and
secretarial assistance. We would also like to thank H Yoshifuji, N Yukawa, D
Kawabata, T Nojima, and T Usui for collecting DNA samples. We thank Y
Katagiri for her technical efforts. We also appreciate the contribution of E
Inoue and other members of the Institute of Rheumatology, Tokyo Women’s
Medical University, for their efforts on the IORRA cohort. This study was
supported in part by grants-in-aid from the Ministry of Education, Culture,
Sports, Science and Technology (MEXT) in Japan, the Ministry of Health,
Labor and Welfare (MHLW) in Japan, the Japan Society for the Promotion of
Science (JSPS), Solution-Oriented Research for Science and Technology
(SORST), the Okawa Foundation for Information and Telecommunications.
Terao et al. Arthritis Research & Therapy  (2015) 17:104 Page 10 of 11Author details
1Center for Genomic Medicine, Kyoto University Graduate School of
Medicine, Kyoto, Japan. 2Department of Rheumatology and Clinical
Immunology, Kyoto University Graduate School of Medicine, Kyoto 606-8507,
Japan. 3Laboratory for Autoimmune Diseases, Center for Genomic Medicine,
RIKEN, Yokohama, Japan. 4Institute of Rheumatology, Tokyo Women’s
Medical University, Tokyo, Japan. 5Department of Human Genetics and
Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo
Medical and Dental University, Tokyo, Japan. 6Division of Rheumatology,
Department of Internal Medicine, Keio University School of Medicine, Tokyo,
Japan. 7Dohgo Spa Hospital, Matsuyama, Japan. 8Department of
Rheumatology, Niigata Rheumatic Center, Niigata, Japan. 9The Centre for
Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan.
10Higashihiroshima Memorial Hospital, Hiroshima, Japan. 11Pharm C,
Matsubara Mayflower Hospital, 944-25 Fujita, Kato City, Hyogo, Japan.
12Kurashiki Sweet Hospital, Kurashiki, Japan. 13Department of the Control for
Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto,
Japan. 14Matsubara Mayflower Hospital, 944-25 Fujita, Kato City, Hyogo,
Japan. 15Institut National de la Sante et de la Recherche Medicale (INSERM)
Unite U852, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Received: 28 July 2014 Accepted: 8 April 2015References
1. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al.
Characterizing the quantitative genetic contribution to rheumatoid arthritis
using data from twins. Arthritis Rheum. 2000;43:30–7.
2. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH,
van’t Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide
antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum.
2000;43:1831–5.
3. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van
Venrooij WJ. Citrulline is an essential constituent of antigenic determinants
recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest.
1998;101:273–81.
4. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM,
Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis
antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum.
2000;43:155–63.
5. Ohmura K, Terao C, Maruya E, Katayama M, Matoba K, Shimada K, et al.
Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a
definitive study using only bone-erosive ACPA-negative rheumatoid arthritis.
Rheumatology (Oxford). 2010;49:2298–304.
6. Terao C, Ohmura K, Kochi Y, Ikari K, Maruya E, Katayama M, et al. A
large-scale association study identified multiple HLA-DRB1 alleles associated
with ACPA-negative rheumatoid arthritis in Japanese subjects. Ann Rheum
Dis. 2011;70:2134–9.
7. Lundstrom E, Kallberg H, Smolnikova M, Ding B, Ronnelid J, Alfredsson L,
et al. Opposing effects of HLA-DRB1*13 alleles on the risk of developing
anti-citrullinated protein antibody-positive and anti-citrullinated protein
antibody-negative rheumatoid arthritis. Arthritis Rheum. 2009;60:924–30.
8. Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F, et al. Regulation of
anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting
effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum.
2005;52:3813–8.
9. Han B, Diogo D, Eyre S, Kallberg H, Zhernakova A, Bowes J, et al. Fine mapping
seronegative and seropositive rheumatoid arthritis to shared and distinct HLA
alleles by adjusting for the effects of heterogeneity. Am J Hum Genet.
2014;94:522–32.
10. Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, Takahashi A, et al. A regulatory
variant in CCR6 is associated with rheumatoid arthritis susceptibility.
Nat Genet. 2010;42:515–9.
11. Suzuki A, Yamada R, Kochi Y, Sawada T, Okada Y, Matsuda K, et al.
Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a
Japanese population. Nat Genet. 2008;40:1224–9.
12. Terao C, Ohmura K, Katayama M, Takahashi M, Kokubo M, Diop G, et al.
Myelin basic protein as a novel genetic risk factor in rheumatoid arthritis–a
genome-wide study combined with immunological analyses. PLoS One.
2011;6:e20457.13. Terao C, Yamada R, Ohmura K, Takahashi M, Kawaguchi T, Kochi Y, et al. The
human AIRE gene at chromosome 21q22 is a genetic determinant for the
predisposition to rheumatoid arthritis in Japanese population. Hum Mol Genet.
2011;20:2680–5.
14. Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, et al. Meta-analysis
identifies nine new loci associated with rheumatoid arthritis in the Japanese
population. Nat Genet. 2012;44:511–6.
15. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, et al.
TRAF1-C5 as a risk locus for rheumatoid arthritis–a genomewide study.
N Engl J Med. 2007;357:1199–209.
16. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al.
STAT4 and the risk of rheumatoid arthritis and systemic lupus
erythematosus. N Engl J Med. 2007;357:977–86.
17. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, et al. Two
independent alleles at 6q23 associated with risk of rheumatoid arthritis.
Nat Genet. 2007;39:1477–82.
18. Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, et al. REL,
encoding a member of the NF-kappaB family of transcription factors, is a
newly defined risk locus for rheumatoid arthritis. Nat Genet. 2009;41:820–3.
19. Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burtt NP, et al.
Common variants at CD40 and other loci confer risk of rheumatoid arthritis.
Nat Genet. 2008;40:1216–23.
20. Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, et al.
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with
rheumatoid arthritis risk. Nat Genet. 2009;41:1313–8.
21. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al.
Genome-wide association study meta-analysis identifies seven new
rheumatoid arthritis risk loci. Nat Genet. 2010;42:508–14.
22. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, et al. High-density
genetic mapping identifies new susceptibility loci for rheumatoid arthritis.
Nat Genet. 2012;44:1336–40.
23. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP,
Alexander HC, et al. A missense single-nucleotide polymorphism in a gene
encoding a protein tyrosine phosphatase (PTPN22) is associated with
rheumatoid arthritis. Am J Hum Genet. 2004;75:330–7.
24. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, et al. A
genome-wide association study suggests contrasting associations in ACPA-positive
versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis. 2011;70:259–65.
25. Bossini-Castillo L, de Kovel C, Kallberg H, van’t Slot R, Italiaander A, Coenen
M, et al. A genome-wide association study of rheumatoid arthritis without
antibodies against citrullinated peptides. Ann Rheum Dis. 2015;74:e15.
26. Skinningsrud B, Lie BA, Husebye ES, Kvien TK, Forre O, Flato B, et al. A
CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic
citrullinated peptide antibody negative rheumatoid arthritis. Ann Rheum
Dis. 2010;69:1471–4.
27. Viatte S, Plant D, Bowes J, Lunt M, Eyre S, Barton A, et al. Genetic markers of
rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody
negative patients. Ann Rheum Dis. 2012;71:1984–90.
28. Wang C, Kokkonen H, Sandling JK, Johansson M, Seddighzadeh M,
Padyukov L, et al. Preferential association of interferon regulatory factor 5
gene variants with seronegative rheumatoid arthritis in 2 Swedish
case–control studies. J Rheumatol. 2011;38:2130–2.
29. Lorentzen JC, Flornes L, Eklow C, Backdahl L, Ribbhammar U, Guo JP, et al.
Association of arthritis with a gene complex encoding C-type lectin-like
receptors. Arthritis Rheum. 2007;56:2620–32.
30. Daha NA, Lie BA, Trouw LA, Stoeken G, Schonkeren JJ, Ding B, et al. Novel
genetic association of the VTCN1 region with rheumatoid arthritis.
Ann Rheum Dis. 2012;71:567–71.
31. Kurreeman F, Liao K, Chibnik L, Hickey B, Stahl E, Gainer V, et al. Genetic
basis of autoantibody positive and negative rheumatoid arthritis risk in a
multi-ethnic cohort derived from electronic health records. Am J Hum
Genet. 2011;88:57–69.
32. Terao C, Ohmura K, Ikari K, Kochi Y, Maruya E, Katayama M, et al. ACPA-Negative
RA Consists of Two Genetically Distinct Subsets Based on RF Positivity in
Japanese. PLoS One. 2012;7:e40067.
33. Mackie SL, Taylor JC, Martin SG, Wordsworth P, Steer S, Wilson AG, et al. A
spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by
autoantibody status in a large UK population. Genes Immun. 2012;13:120–8.
34. Jiang L, Yin J, Ye L, Yang J, Hemani G, Liu AJ, et al. Novel risk loci for
rheumatoid arthritis in han chinese and congruence with risk variants in
europeans. Arthritis Rheumatol. 2014;66:1121–32.
Terao et al. Arthritis Research & Therapy  (2015) 17:104 Page 11 of 1135. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
36. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al.
2010 Rheumatoid arthritis classification criteria: an American College of
Rheumatology/European League Against Rheumatism collaborative
initiative. Arthritis Rheum. 2010;62:2569–81.
37. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al.
PLINK: a tool set for whole-genome association and population-based
linkage analyses. Am J Hum Genet. 2007;81:559–75.
38. Kochi Y, Yamada R, Suzuki A, Harley JB, Shirasawa S, Sawada T, et al. A
functional variant in FCRL3, encoding Fc receptor-like 3, is associated with
rheumatoid arthritis and several autoimmunities. Nat Genet. 2005;37:478–85.
39. Sun LD, Cheng H, Wang ZX, Zhang AP, Wang PG, Xu JH, et al. Association
analyses identify six new psoriasis susceptibility loci in the Chinese
population. Nat Genet. 2010;42:1005–9.
40. Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, et al. A genome-wide
association study identifies novel and functionally related susceptibility Loci for
Kawasaki disease. PLoS Genet. 2009;5:e1000319.
41. Havik B, Le Hellard S, Rietschel M, Lybaek H, Djurovic S, Mattheisen M, et al.
The complement control-related genes CSMD1 and CSMD2 associate to
schizophrenia. Biol Psychiatry. 2011;70:35–42.
42. Tang MR, Wang YX, Guo S, Han SY, Wang D. CSMD1 exhibits antitumor
activity in A375 melanoma cells through activation of the Smad pathway.
Apoptosis. 2012;17:927–37.
43. Kraus DM, Elliott GS, Chute H, Horan T, Pfenninger KH, Sanford SD, et al.
CSMD1 is a novel multiple domain complement-regulatory protein highly
expressed in the central nervous system and epithelial tissues. J Immunol.
2006;176:4419–30.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
